Liampas Ioannis, Demiri Silvia, Siokas Vasileios, Tsika Antonia, Marogianni Chrysa, Stamati Polyxeni, Nasios Grigorios, Messinis Lambros, Lyketsos Constantine G, Dardiotis Efthimios
Department of Neurology, University Hospital of Larissa, School of Medicine, University of Thessaly, 41100 Larissa, Greece.
School of Medicine, University of Patras, 26504 Patras, Greece.
Int J Mol Sci. 2025 Sep 3;26(17):8562. doi: 10.3390/ijms26178562.
We investigated associations between () alleles and motor manifestations in Alzheimer's dementia (AD) capitalizing on National Alzheimer's Coordinating Center data: the baseline evaluations of older adults (≥60 years) with a diagnosis of AD were analyzed. Those with a concomitant diagnosis Parkinson's disease or other parkinsonian syndrome, and those treated with anti-parkinsonian agents were excluded. Three groups were formed: ( carriers), () and (). UPDRS-III was used to assess the presence or absence of motor signs in 9 domains. Adjusted binary logistic models featuring the three groups as exposures and motor domains as outcomes were estimated. There were 389 individuals in the , 1799 in the and 2791 in the groups. Compared to the group, individuals in the APOE4 group had lower odds of having at least one motor sign [0.64 (0.50-0.82)]. Among motor signs, rigidity [0.53 (0.34-0.81)], bradykinesia [0.56 (0.40-0.77)], impaired chair rise [0.54 (0.37-0.78)] and impaired posture-gait [0.54 (0.36, 0.81)] exhibited significant associations. Exploratory analyses featuring genotypes suggested dose-response relationships for both and . In conclusion, confers a risk towards motor (mainly parkinsonian) signs in AD. may have a protective effect.
我们利用国家阿尔茨海默病协调中心的数据，研究了阿尔茨海默病（AD）中（）等位基因与运动表现之间的关联：对诊断为AD的老年人（≥60岁）的基线评估进行了分析。排除了伴有帕金森病或其他帕金森综合征诊断的患者，以及接受抗帕金森药物治疗的患者。形成了三组：（携带者）、（）和（）。使用统一帕金森病评定量表第三部分（UPDRS-III）评估9个领域中运动体征的有无。估计了以三组为暴露因素、运动领域为结局的校正二元逻辑模型。组中有389人，组中有1799人，组中有2791人。与组相比，APOE4组个体出现至少一种运动体征的几率较低[0.64（0.50 - 0.82）]。在运动体征中，强直[0.53（0.34 - 0.81）]、运动迟缓[0.56（0.40 - 0.77）]、从椅子上站起困难[0.54（0.37 - 0.78）]和姿势步态障碍[0.54（0.36，0.81）]表现出显著关联。对基因型的探索性分析表明，和均存在剂量反应关系。总之，在AD中赋予运动（主要是帕金森样）体征风险。可能具有保护作用。
